vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and RH (RH). Click either name above to swap in a different company.
RH is the larger business by last-quarter revenue ($883.8M vs $708.5M, roughly 1.2× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 4.1%, a 15.0% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 8.9%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $83.0M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 9.4%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
RH is an upscale American home-furnishings company headquartered in Corte Madera, California. The company sells its merchandise through its retail stores, catalog, and online. As of August 2018, the company operated a total of 70 galleries, 18 full-line design galleries, and 3 baby-and-child galleries. The company also has 36 outlet stores in the United States and Canada.
MEDP vs RH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $883.8M |
| Net Profit | $135.1M | $36.3M |
| Gross Margin | — | 44.1% |
| Operating Margin | 21.6% | 12.0% |
| Net Margin | 19.1% | 4.1% |
| Revenue YoY | 32.0% | 8.9% |
| Net Profit YoY | 15.5% | 9.3% |
| EPS (diluted) | $4.65 | $1.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $883.8M | ||
| Q3 25 | $659.9M | $899.2M | ||
| Q2 25 | $603.3M | $814.0M | ||
| Q1 25 | $558.6M | $812.4M | ||
| Q4 24 | $536.6M | $811.7M | ||
| Q3 24 | $533.3M | $829.7M | ||
| Q2 24 | $528.1M | $727.0M | ||
| Q1 24 | $511.0M | $738.3M |
| Q4 25 | $135.1M | $36.3M | ||
| Q3 25 | $111.1M | $51.7M | ||
| Q2 25 | $90.3M | $8.0M | ||
| Q1 25 | $114.6M | $13.9M | ||
| Q4 24 | $117.0M | $33.2M | ||
| Q3 24 | $96.4M | $29.0M | ||
| Q2 24 | $88.4M | $-3.6M | ||
| Q1 24 | $102.6M | $11.4M |
| Q4 25 | — | 44.1% | ||
| Q3 25 | — | 45.5% | ||
| Q2 25 | — | 43.7% | ||
| Q1 25 | — | 44.7% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.2% | ||
| Q2 24 | — | 43.5% | ||
| Q1 24 | — | 43.5% |
| Q4 25 | 21.6% | 12.0% | ||
| Q3 25 | 21.5% | 14.3% | ||
| Q2 25 | 20.9% | 6.9% | ||
| Q1 25 | 20.3% | 8.7% | ||
| Q4 24 | 23.4% | 12.5% | ||
| Q3 24 | 21.1% | 11.6% | ||
| Q2 24 | 19.9% | 7.5% | ||
| Q1 24 | 20.4% | 8.7% |
| Q4 25 | 19.1% | 4.1% | ||
| Q3 25 | 16.8% | 5.8% | ||
| Q2 25 | 15.0% | 1.0% | ||
| Q1 25 | 20.5% | 1.7% | ||
| Q4 24 | 21.8% | 4.1% | ||
| Q3 24 | 18.1% | 3.5% | ||
| Q2 24 | 16.7% | -0.5% | ||
| Q1 24 | 20.1% | 1.5% |
| Q4 25 | $4.65 | $1.83 | ||
| Q3 25 | $3.86 | $2.62 | ||
| Q2 25 | $3.10 | $0.40 | ||
| Q1 25 | $3.67 | $0.71 | ||
| Q4 24 | $3.67 | $1.66 | ||
| Q3 24 | $3.01 | $1.45 | ||
| Q2 24 | $2.75 | $-0.20 | ||
| Q1 24 | $3.20 | $0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $43.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $3.3M |
| Total Assets | $2.0B | $4.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $43.1M | ||
| Q3 25 | $285.4M | $34.6M | ||
| Q2 25 | $46.3M | $46.1M | ||
| Q1 25 | $441.4M | $30.4M | ||
| Q4 24 | $669.4M | $87.0M | ||
| Q3 24 | $656.9M | $78.3M | ||
| Q2 24 | $510.9M | $101.8M | ||
| Q1 24 | $407.0M | $123.7M |
| Q4 25 | $459.1M | $3.3M | ||
| Q3 25 | $293.6M | $-40.9M | ||
| Q2 25 | $172.4M | $-110.8M | ||
| Q1 25 | $593.6M | $-163.6M | ||
| Q4 24 | $825.5M | $-183.0M | ||
| Q3 24 | $881.4M | $-234.7M | ||
| Q2 24 | $763.6M | $-289.9M | ||
| Q1 24 | $671.5M | $-297.4M |
| Q4 25 | $2.0B | $4.8B | ||
| Q3 25 | $1.8B | $4.7B | ||
| Q2 25 | $1.6B | $4.7B | ||
| Q1 25 | $1.9B | $4.6B | ||
| Q4 24 | $2.1B | $4.5B | ||
| Q3 24 | $2.1B | $4.4B | ||
| Q2 24 | $1.9B | $4.2B | ||
| Q1 24 | $1.8B | $4.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $131.9M |
| Free Cash FlowOCF − Capex | $188.1M | $83.0M |
| FCF MarginFCF / Revenue | 26.6% | 9.4% |
| Capex IntensityCapex / Revenue | 0.6% | 5.5% |
| Cash ConversionOCF / Net Profit | 1.43× | 3.64× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $128.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $131.9M | ||
| Q3 25 | $246.2M | $137.7M | ||
| Q2 25 | $148.5M | $86.6M | ||
| Q1 25 | $125.8M | $-18.8M | ||
| Q4 24 | $190.7M | $-31.4M | ||
| Q3 24 | $149.1M | $11.2M | ||
| Q2 24 | $116.4M | $56.1M | ||
| Q1 24 | $152.7M | $-114.0M |
| Q4 25 | $188.1M | $83.0M | ||
| Q3 25 | $235.5M | $80.7M | ||
| Q2 25 | $142.4M | $34.1M | ||
| Q1 25 | $115.8M | $-69.7M | ||
| Q4 24 | $183.0M | $-96.0M | ||
| Q3 24 | $138.5M | $-37.9M | ||
| Q2 24 | $103.5M | $-10.1M | ||
| Q1 24 | $147.2M | $-251.5M |
| Q4 25 | 26.6% | 9.4% | ||
| Q3 25 | 35.7% | 9.0% | ||
| Q2 25 | 23.6% | 4.2% | ||
| Q1 25 | 20.7% | -8.6% | ||
| Q4 24 | 34.1% | -11.8% | ||
| Q3 24 | 26.0% | -4.6% | ||
| Q2 24 | 19.6% | -1.4% | ||
| Q1 24 | 28.8% | -34.1% |
| Q4 25 | 0.6% | 5.5% | ||
| Q3 25 | 1.6% | 6.3% | ||
| Q2 25 | 1.0% | 6.5% | ||
| Q1 25 | 1.8% | 6.3% | ||
| Q4 24 | 1.4% | 8.0% | ||
| Q3 24 | 2.0% | 5.9% | ||
| Q2 24 | 2.4% | 9.1% | ||
| Q1 24 | 1.1% | 18.6% |
| Q4 25 | 1.43× | 3.64× | ||
| Q3 25 | 2.22× | 2.66× | ||
| Q2 25 | 1.65× | 10.78× | ||
| Q1 25 | 1.10× | -1.35× | ||
| Q4 24 | 1.63× | -0.95× | ||
| Q3 24 | 1.55× | 0.39× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | -10.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RH
| RH Segment | $835.8M | 95% |
| Waterworks Segment | $48.0M | 5% |
| Gift Card And Merchandise Credit | $4.5M | 1% |
